Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of Human Botulism Immunoglobulin in Infants With Botulism

This study has been completed.
Information provided by:
FDA Office of Orphan Products Development Identifier:
First received: October 18, 1999
Last updated: March 24, 2015
Last verified: March 2000

OBJECTIVES: I. Determine the safety of human botulism immune globulin (BIG) in patients with infant botulism by monitoring side effects (e.g., rash, fever, hypotension, and anaphylaxis).

II. Assess the efficacy of BIG in these patients by monitoring disease severity, incidence of complications (respiratory arrest, aspiration, pneumonia, etc.), and length of hospital stay.

Condition Intervention
Infant Botulism
Drug: botulism immune globulin

Study Type: Interventional
Study Design: Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by FDA Office of Orphan Products Development:

Estimated Enrollment: 120
Study Start Date: January 1998
Estimated Study Completion Date: June 1998
Detailed Description:

PROTOCOL OUTLINE: This is an open label, multicenter study. Patients should begin therapy within 72 hours of hospital admission, but may receive human botulism immunoglobulin (BIG) in certain circumstances after 72 hours. Patients receive (BIG) IV. Patients are monitored for side effects, disease severity, complications, and length of hospital stay.

Patients are followed at 2 weeks after treatment, then every 4 weeks for 6 months.

Completion date provided represents the completion date of the grant per OOPD records


Ages Eligible for Study:   up to 1 Year   (Child)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No


--Disease Characteristics--

  • Clinical diagnosis of infant botulism in previously healthy infant
  • Bulbar palsies
  • Constipated Lethargy
  • Diminished head control
  • Poor feeding
  • Generalized weakness and hypotonia
  • Weak cry
  • Afebrile (unless secondary infection present)
  • Subacute to acute onset
  • Normal electrolytes
  • Any patient eligible provided no treatment available for life-threatening condition
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00004401

United States, California
California Department of Health Services
Berkeley, California, United States, 94704-1011
Sponsors and Collaborators
California Department of Health Services
Study Chair: Stephen S. Arnon California Department of Health Services
  More Information Identifier: NCT00004401     History of Changes
Other Study ID Numbers: 199/13253  CDHS-FDU000476 
Study First Received: October 18, 1999
Last Updated: March 24, 2015
Health Authority: United States: Federal Government

Keywords provided by FDA Office of Orphan Products Development:
bacterial infection
clostridium infection
immunologic disorders and infectious disorders
infant botulism
rare disease

Additional relevant MeSH terms:
Clostridium Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Neuromuscular Junction Diseases
Neuromuscular Diseases
Nervous System Diseases
Neurotoxicity Syndromes
Foodborne Diseases
Chemically-Induced Disorders
Immunoglobulins, Intravenous
Rho(D) Immune Globulin
Immunologic Factors
Physiological Effects of Drugs processed this record on October 25, 2016